Biogen’s and Eisai’s Alzheimer’s Therapy Grabs FDA Priority Review

The FDA has granted Biogen’s and Eisai’s investigational Alzheimer’s treatment aducanumab a priority review.

The drug’s approval would make aducanumab the first therapy to reduce clinical decline in Alzheimer’s patients and the first to show that removing amyloid beta improves clinical outcomes.

The agency is expected to issue a decision on the drug’s approval by March 7, 2021.